Effectiveness of oral sotalol for treatment of pediatric arrhythmias.
Effectiveness of oral sotalol for treatment of pediatric arrhythmias.
复制标题
口服索他洛尔治疗小儿心律失常的有效性。
DOI：
10.1016/0002-9149(92)90500-x
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
A. Fournier
中科院分区：
文献类型：
--
作者：
P. Maragnès;M. Tipple;A. Fournier
索他洛尔是一种具有III类活性的β受体阻滞剂。很少有研究者报告其在儿科患者中的使用。从1985年8月至1990年5月，66例患者（平均年龄8.7岁;范围9天至24岁），包括14名年龄<3个月的婴儿，接受口服索他洛尔单独治疗（n = 46）或与地高辛联合治疗（n = 20）。室上性折返性心动过速38例（20例有预激记录），房扑10例，房性异位心动过速7例。3例患者有其他类型的室上性心动过速。心动过速6例为室性心动过速，2例同时为室上性和室性心动过速。口服索他洛尔的平均剂量为135 mg/m2/天，分2次给药。28例患者存在先天性心脏病，其中14例既往接受过心脏手术，主要发生在心房水平。83%的患者既往接受过1种或多种抗肿瘤药物治疗，但治疗失败。平均治疗持续时间为13.3个月（范围2个月至5年）。总体而言，79%的病例治疗成功。成功率最高的是室上性折返性心动过速伴或不伴预激（89%）和房性异位心动过速（85.5%）。60%的病例心房扑动得到控制。索他洛尔对室性心动过速的疗效似乎较差，仅17%的患者完全控制了心律失常;然而，索他洛尔可减少50%患者的室性心动过速发作次数和室性早搏次数。89%的患者无不良反应。2例既往有病窦综合征的患者心动过缓恶化，1例需要植入起搏器。索他洛尔是一种非常有效的药物，用于治疗各种儿科心律失常，特别是室上性心律失常，无显著不良反应。
Sotalol is a β blocker with class III activity. Few investigators have reported its use in pediatric patients. From August 1985 to May 1990, 66 patients (mean age 8.7 years; range 9 days to 24 years), including 14 infants aged <3 months, were treated with oral sotalol alone (n = 46) or in association with digoxin (n = 20). Supraventricular reentrant tachycardia was present in 38 patients (20 with documented preexcitation), atrial flutter in 10 and atrial ectopic tachycardia in 7. Three patients had other types of supraventricular tachycardia. Tachycardia was of ventricular origin in 6 patients and both of supraventricular and ventricular origin in the remaining 2. Mean dose of oral sotalol was 135 mg/m2/day given in 2 doses. Congenital heart disease was present in 28 patients, 14 with previous cardiac surgery, mostly at the atrial level. Prior treatment with 1 or more antiarrhythmic agent had been unsuccessful in 83% of patients. Mean duration of treatment was 13.3 months (range 2 months to 5 years). Overall, treatment was successful in 79% of cases. Highest rate of success was observed in patients with supraventricular reentrant tachycardia with or without preexcitation (89%) and in those with atrial ectopic tachycardia (85.5%). Atrial flutter could be controlled in 60% of cases. Sotalol seemed less effective in ventricular tachycardia with a complete control of the arrhythmia being achieved in only 17%; however, it decreased the number of runs of ventricular tachycardia and the number of ventricular premature complexes in 50% of patients. There were no adverse effects in 89% of patients. Two patients with previous sick sinus syndrome had worsening of their bradycardia necessitating implantation of a pacemaker in 1. Sotalol is a very effective drug for the treatment of the various Pediatric arrhythmias, in particular supraventricular arrhythmias, without significant adverse effects.
室性心律失常的自发变异性分析：室性心动过速的连续动态心电图记录。
DOI：
10.1016/0002-9149(85)90568-5
发表时间：
1985
期刊：
The American journal of cardiology
影响因子：
--
作者：
Pratt,CM;Slymen,DJ;Wierman,AM;Young,JB;Francis,MJ;Seals,AA;Quinones,MA;Roberts,R
通讯作者：
Roberts,R